Alec Stranahan
Stock Analyst at B of A Securities
(0.80)
# 4,033
Out of 5,124 analysts
32
Total ratings
40%
Success rate
-25.39%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alec Stranahan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KRYS Krystal Biotech | Maintains: Buy | $182 → $255 | $246.54 | +3.43% | 5 | Oct 17, 2025 | |
| CADL Candel Therapeutics | Downgrades: Neutral | $13 → $7 | $5.65 | +23.89% | 2 | Sep 3, 2025 | |
| XNCR Xencor | Downgrades: Neutral | $23 → $12 | $15.31 | -21.62% | 2 | Sep 3, 2025 | |
| ERAS Erasca | Downgrades: Underperform | $4 → $1 | $3.72 | -73.12% | 3 | Sep 3, 2025 | |
| NVAX Novavax | Downgrades: Underperform | $9 → $7 | $6.72 | +4.17% | 5 | Aug 20, 2025 | |
| BEAM Beam Therapeutics | Upgrades: Buy | $42 | $27.72 | +51.52% | 1 | Mar 28, 2025 | |
| DAWN Day One Biopharmaceuticals | Maintains: Buy | $28 → $25 | $9.32 | +168.24% | 5 | Jan 7, 2025 | |
| CRBU Caribou Biosciences | Maintains: Buy | $13 → $11 | $1.59 | +591.82% | 1 | Jan 7, 2025 | |
| CATX Perspective Therapeutics | Downgrades: Neutral | $24 → $6 | $2.75 | +118.18% | 2 | Nov 25, 2024 | |
| EDIT Editas Medicine | Upgrades: Buy | $13 → $15 | $2.05 | +631.71% | 1 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $48 → $55 | $79.65 | -30.95% | 3 | Jul 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $5 → $6 | $29.81 | -79.87% | 2 | Dec 29, 2022 |
Krystal Biotech
Oct 17, 2025
Maintains: Buy
Price Target: $182 → $255
Current: $246.54
Upside: +3.43%
Candel Therapeutics
Sep 3, 2025
Downgrades: Neutral
Price Target: $13 → $7
Current: $5.65
Upside: +23.89%
Xencor
Sep 3, 2025
Downgrades: Neutral
Price Target: $23 → $12
Current: $15.31
Upside: -21.62%
Erasca
Sep 3, 2025
Downgrades: Underperform
Price Target: $4 → $1
Current: $3.72
Upside: -73.12%
Novavax
Aug 20, 2025
Downgrades: Underperform
Price Target: $9 → $7
Current: $6.72
Upside: +4.17%
Beam Therapeutics
Mar 28, 2025
Upgrades: Buy
Price Target: $42
Current: $27.72
Upside: +51.52%
Day One Biopharmaceuticals
Jan 7, 2025
Maintains: Buy
Price Target: $28 → $25
Current: $9.32
Upside: +168.24%
Caribou Biosciences
Jan 7, 2025
Maintains: Buy
Price Target: $13 → $11
Current: $1.59
Upside: +591.82%
Perspective Therapeutics
Nov 25, 2024
Downgrades: Neutral
Price Target: $24 → $6
Current: $2.75
Upside: +118.18%
Editas Medicine
Aug 8, 2024
Upgrades: Buy
Price Target: $13 → $15
Current: $2.05
Upside: +631.71%
Jul 16, 2024
Maintains: Buy
Price Target: $48 → $55
Current: $79.65
Upside: -30.95%
Dec 29, 2022
Maintains: Underperform
Price Target: $5 → $6
Current: $29.81
Upside: -79.87%